<SEC-DOCUMENT>0001493152-26-036229.txt : 20260806
<SEC-HEADER>0001493152-26-036229.hdr.sgml : 20260806
<ACCEPTANCE-DATETIME>20260805181322
ACCESSION NUMBER:		0001493152-26-036229
CONFORMED SUBMISSION TYPE:	425
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260806
DATE AS OF CHANGE:		20260805

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41615
		FILM NUMBER:		261245229

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		425

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
</SEC-HEADER>
<DOCUMENT>
<TYPE>425
<SEQUENCE>1
<FILENAME>form425.htm
<DESCRIPTION>425
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">Filed by Mangoceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">Pursuant to Rule 425 under the Securities Act of 1933, as amended,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">and deemed filed pursuant to Rule 14a-12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">under
the Securities Exchange Act of 1934, as amended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">Subject Company: Nuclea Energy Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">Commission File No.: 001-41615</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 5, 2026, Mangoceuticals, Inc. issued the following press release</FONT> </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="form425_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mangoceuticals&rsquo;
Merger Partner, Nuclea Energy (&ldquo;Nuclea&rdquo;), Executes MOU with Utah Office of Energy Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of
Energy and Nuclear Regulatory Commission to advance the Morpheus microreactor toward demonstration and deployment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas &ndash; August 5, 2026 &ndash; Mangoceuticals, Inc. (NASDAQ: MGRX) (&ldquo;Mangoceuticals&rdquo; or the &ldquo;Company&rdquo;)
today announced that its merger partner&rsquo;s wholly owned subsidiary, Nuclea Energy USA Inc. (&ldquo;Nuclea USA&rdquo;), has signed
a memorandum of understanding (the &ldquo;MOU&rdquo;) with the State of Utah Office of Energy Development (&ldquo;OED&rdquo;) to explore
the siting of a nuclear test reactor at the Utah San Rafael Energy Lab (&ldquo;USREL&rdquo;) to advance the deployment of the Morpheus
microreactor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MOU marks an important step in advancing research, development and commercial deployment of Nuclea&rsquo;s micro-modular reactor. The
partnership established in the MOU will allow Nuclea and OED to explore siting a nuclear test reactor at USREL, support engagement with
both the U.S. Department of Energy (DOE) and the Nuclear Regulatory Commission (NRC), and evaluate pathways for future deployment of
Nuclea&rsquo;s technology in Utah. Through this partnership, the parties aim to strengthen Utah&rsquo;s role as a hub for advanced nuclear
innovation, testing and demonstration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
Utah&rsquo;s energy leadership and ambition, USREL has become a premier hub for advanced nuclear technology testing and development.
Nuclea is proud to be joining several other industry innovators, including Valar Atomics and Natura Resources, leading significant research
and development projects at USREL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are excited to be contributing to and benefitting from the nuclear innovation hub that Utah has fostered at USREL. We are confident that
this partnership will help to prove the inherent advantages of our technology and accelerate our deployment schedule,&rdquo; said Josef
Freundorfer, CEO of Nuclea.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Nuclea
is proud to partner with the State of Utah on the next step in our technology&rsquo;s development. We are thrilled to be working with
USREL given its proven track record of demonstrating advanced power generation technologies,&rdquo; said Sagar Sanghera, Chairman &amp;
Co-Founder of Nuclea.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Utah
is leading the nation in energy innovation, and our partnership with Nuclea is another step towards an abundant energy future that is
reliable, secure and clean,&rdquo; said Emy Lesofski, Director, Energy Advisor to the Governor and Director of the Utah Office of Energy
Development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;This
MOU represents meaningful progress for our merger partner and underscores the strategic value of the business combination we announced
last week,&rdquo; said Jacob Cohen, Chief Executive Officer of Mangoceuticals. &ldquo;Nuclea&rsquo;s engagement with the Utah Office
of Energy Development, and the planned collaboration with the Department of Energy and Nuclear Regulatory Commission, positions the Morpheus
microreactor for accelerated advancement toward demonstration and commercial deployment. We remain focused on completing the transaction
and unlocking long-term value for our shareholders.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
agreement reflects Nuclea&rsquo;s continued progress in building the partnerships needed to advance research, testing, and demonstration
activities for the Morpheus microreactor, showcasing the innovative capabilities and inherent safety features of its compact lead-cooled
reactor technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 30, 2026, Mangoceuticals announced that it had entered into a definitive business combination agreement (the &ldquo;Business Combination
Agreement&rdquo;) with Nuclea.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
proposed transaction is intended to provide Nuclea with a path to a Nasdaq public listing through Mangoceuticals, broadening access to
the capital markets to fund the continued development, licensing, and commercialization of the Morpheus microreactor at a time when demand
for consistent baseload electricity is accelerating.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
of the business combination remains subject to customary closing conditions, including the receipt of required stockholder and regulatory
approvals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Utah Office of Energy Development</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Utah Office of Energy Development (&ldquo;OED&rdquo;) is Utah&rsquo;s primary office responsible for energy and mineral development.
The office is charged with developing and implementing energy policy and resources, creating energy-related educational and workforce
development programs and promoting energy efficiency and modern, resilient infrastructure. <U>https://energy.utah.gov/</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Utah San Rafael Energy Lab</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Utah San Rafael Energy Lab (&ldquo;USREL&rdquo;) is Utah&rsquo;s leading hub for energy research and innovation. Located in Emery County,
UT, the USREL supports Utah&rsquo;s any-of-the-above energy strategy by hosting a wide range of cutting-edge projects. With state-of-the-art
facilities, a team of expert researchers and staff and space for future growth, the USREL is advancing energy solutions to some of today&rsquo;s
most pressing challenges. <U>https://energylab.utah.gov/</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nuclea Energy Inc.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nuclea
Energy Inc. (&ldquo;Nuclea&rdquo;) is an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus
microreactor, a lead-cooled, graphite-moderated micro-modular reactor designed to be factory-built, transportable and scalable from approximately
3.5 MWe to 50 MWe. Nuclea is targeting applications across data centers, defense installations, remote industrial operations and off-grid
communities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information on Nuclea and the Morpheus&trade; microreactor please visit: <U>https://www.nuclea.energy</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nuclea
media contact: <U>media@nuclea.energy</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utah
OED Public Information Officer contact: <U>hmcshane@utah.gov</U>.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Mangoceuticals, Inc.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Inc., through its subsidiary Mango and Peaches Corp., and its brand, MangoRx, is continued to be focused on developing a variety of men&rsquo;s
health and wellness products and services via a secure telemedicine platform. To date, the Company currently offers pharmaceutical-based
products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management.
Interested consumers can use MangoRx&rsquo;s telemedicine platform for a smooth experience. Prescription requests will be reviewed by
a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx&rsquo;s partner compounding pharmacy and
right to the patient&rsquo;s doorstep.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
learn more about MangoRx&rsquo;s mission and other products, please visit <U>www.MangoRx.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements contained in this news release constitute &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities
Litigation Reform Act of 1995, including with respect to the proposed business combination between Nuclea and Mangoceuticals (the &ldquo;Proposed
Transaction&rdquo;). These forward-looking statements generally are identified by the words &ldquo;believe,&rdquo; &ldquo;project,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;think,&rdquo; &ldquo;strategy,&rdquo;
&ldquo;future,&rdquo; &ldquo;opportunity,&rdquo; &ldquo;potential,&rdquo; &ldquo;plan,&rdquo; &ldquo;seeks,&rdquo; &ldquo;may,&rdquo;
&ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;will be,&rdquo; &ldquo;will continue,&rdquo; &ldquo;will likely
result,&rdquo; and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking
statements represent Nuclea&rsquo;s expectations or beliefs concerning guidance, future events, anticipated revenue, future demand and
production levels, macroeconomic trends, the development of ongoing projects, costs and expectations, and it is possible that the results
described in this news release will not be achieved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of Nuclea&rsquo;s control,
which could cause actual results to differ materially from the results discussed in the forward-looking statements. These factors include,
without limitation: our ability to advance our proposed products from their current pre-conceptual stage to regulatory and commercial
readiness; the risk that we may be unable to realize our anticipated growth strategies, including the achievement of key regulatory and
technical milestones, commercialization and our expected internal growth; changes in the availability and cost of professional staff
and materials; changes in consumer preferences and needs, in our future capital needs and/or in competitive conditions; among others.
In addition, there is a risk that the Proposed Transaction may not be completed in a timely manner or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Nuclea does not undertake any
obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New
factors emerge from time to time, and it is not possible for Nuclea to predict all such factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Important
Notices and Additional Information</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Proposed Transaction, Mangoceuticals intends to file a registration statement on Form S-4 containing a prospectus
with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;). <B>INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THE REGISTRATION
STATEMENT/PROSPECTUS WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PARTIES AND THE PROPOSED TRANSACTION.</B>
Investors and security holders may obtain a free copy of the prospectus, the proxy statement and other documents filed by Mangoceuticals
and Nuclea (in each case when available) with the SEC at the SEC&rsquo;s website at <U>http://www.sec.gov</U>. Free copies of these documents
and other filings with the SEC may also be obtained by contacting Mangoceuticals directly at <U>ir@nuclea.energy</U> or Nuclea at <U>ir@nuclea.energy</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participants
in the Solicitation</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Nuclea and their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed
to be participants in the solicitation of proxies from Mangoceuticals&rsquo; stockholders in connection with the transaction. Investors
and security holders may obtain more detailed information regarding the names, affiliations and interests of Mangoceuticals&rsquo; executive
officers and directors in its most recent Annual Report on Form 10-K and other filings with the SEC. Additional information regarding
the persons who may be deemed participants in the solicitation and their interests will be set forth in the proxy statement and other
relevant materials when they become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
Offer or Solicitation</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
news release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect
of the Proposed Transaction contemplated by the Business Combination Agreement and shall not constitute an offer to sell or a solicitation
of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any state
or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements
of the Securities Act of 1933, as amended, or an exemption therefrom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
INVESTOR RELATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nuclea
Energy Inc.</B><BR>
CORE IR<BR>
<U>ir@nuclea.energy</U><BR>
(437) 784-1600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mangoceuticals,
Inc.</B><BR>
<U>investors@mangorx.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>form425_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 form425_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  X 0<# 2(  A$! Q$!_\0
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MH-NRLVVH))WE**M?Z$HK\J=2_P""IGPHM[CR-'^'WC^^A/6ZN4\.:9'WZ?\
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MM5NBDVE:3:Z%H[^(=&3:S^5J^L: 8_#TK.JE/L]L;D*Q0MXDN"PKUW6OC/\
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MYI571O@(J7L=?[3;:62M6S-X=W2]*HHHKUSG"O\ )5_X.3?^4U_[;/\ U^?
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M5XG\6,#XTUM88_\ A+8U_P"$-\$_!'_!QA_RF@_;@_['#X8?^L^?"&O[F?\
M@UH@AB_X(X_ F:WA%L;KXB_':[N< $W3O\4/$:F3/7!^3 _V#CKR ?FC\0O^
M#,?]G2[\&WT'PM_;'^-NB?$'['_Q*]3^('A'P9XF\$7NI\X;6M"T >$?$[J<
M8.WQ>6!. K$,!_"9\>?@G\1OV5_C[\4/@3\1H!HGQ0^"/Q(\3^"_$G]DW?\
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M+*9FW2 1KF( _P 8[XD7GC[4OB-\0+[XJ7'B2Y^*%UXP\47OQ(N_%G/B:_\
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MA)4;)61'P59&'S!LC<"#TY']4WB;XL_#;P7I[ZOXO\>^%?#]I; ^;)J6NZ9
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M]_8L_P"";'P@_9Y_:7\#/\./B]X5\7?&'5M8\+GQ)X/\8II^F>)/B;XA\0Z
MT?B#P%X@\4>%YLZ!K%NC+;798R-MD6-D^?\ :&B@ K_.2_X*^?\ !!;_ (*J
M?M3_ /!2+]J[X_\ P*_9@M/&GPI^)WCK3-:\#^+/^%W_  #\.C6]+C\%>'M
M?.C^)/B1X/\ %6@[6T3#,Z*V-K-@L0/]&VB@#\/_ /@CM^PQXR^#?_!('X5_
ML3_MO_"/3]*\176C?'CPO\8/A5K/B'PGXOTW4?"_Q6^,?Q#\0)HMQKG@'Q/X
MG\,O;^(O#/B+2VD@\.>+'2*YE7;Y-U$V/Y*_^"A?_!IU^U[\(?''B'QA^PG+
MIW[2_P &+J]U"]T7P3JGB70_!OQN\#Z4Z;SI&M/KS>$?#7C^,,#&OBOPSXLB
M\:2.K >!L&,R?Z2E% '^.=_PYH_X*R6>L_V5;_L"?M56^H$?8Q=VGPKUC^S"
M#T/]N?\ (L8]SGO7ZR?L(_\ !J?^WA\>_&FA:U^V+#IW[)OP9%W]M\26=SXD
M\&^-OCCXJTW*,-#\%Z-H \7>%/#;2*X$7B;Q@\9\'E@R^"/&@5@?],VB@#_*
M]_:7_P"#;S_@J/9?M%_'^R_9[_8OUG4?V?K;XU?%&U^"=VWQL^ :F^^#*^--
M?_X522/$?QL'BA0OALZ$3_PEH_X31<@-@U_5-\:/^">7[8/CG_@VE\$_L ^'
MO@YY_P"UMI7@#X-Z+>_"JZ\=?#/3_LFK^!OV@_#WCO61_P )OKWB8_#?<OAW
M07\1KCQ6T<CNL,<IG/DG^IRB@#_.+_X)&_\ !!?_ (*M?LO?\%(/V4/C[\;_
M -F&T\%?"GX8?$;4];\<^*Q\;O@#XC_L/27\%>(= 4C1O#OQ)\7>*?$&YM;P
MI16)Y*\@ _Z.E%% !7\0G_!R5_P2$_X*"_\ !0+]MKX1_&#]DCX"6WQ1^'_A
M/]EGPQ\--;\0R?%'X.>!#8>.]&^)OQ<\2/I7]B_$'XC^#_$4Z/X?\=Z,QN(
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
